(4-methoxyquinolin-2-yl)methanol | 361576-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (4-methoxyquinolin-2-yl)methanol
• 英文别名: 4-methoxyquinoline-2-methanol
• CAS: 361576-36-5
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: XXWJSGLSCJRCSW-UHFFFAOYSA-N

物化性质

• 沸点：
  318.2±27.0 °C(Predicted)
• 密度：
  1.223±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Phosphoric acid di-tert-butyl ester (R)-3-(4-hydroxy-phenyl)-2-((Z)-octadec-9-enoylamino)-propyl ester 、 (4-methoxyquinolin-2-yl)methanol 在 三丁基膦 、 偶氮二甲酸二异丙酯 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist

  摘要：

  A recently reported dual LPA(1)/LPA(3) receptor antagonist (1) has been modified so as to modulate the basicity, sterics, and dipole moment of the 2-pyridyl moiety. Additionally, the implications of installing nonhydrolyzable phosphate head group isosteres with regard to antagonist potency and selectivity at LPA receptors is described. This study has resulted in the development of the first nonhydrolyzable and presumably phosphatase-resistant LPA(3)-selective antagonist reported to date. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.023
• 作为产物：
  描述：

  4-甲氧基喹啉-2-羧酸甲酯 生成 (4-methoxyquinolin-2-yl)methanol
  参考文献：
  名称：

  Quinoline derivatives and medicinal use thereof

  摘要：

  由以下式（1）表示的喹啉衍生物，可以使作为细胞核转录因子的PPAR&agr;或&ggr;功能强大且毒性低。通过使用这种化合物作为活性成分，可以提供与PPAR&agr;或&ggr;相关的各种疾病的预防或治疗剂。

  公开号：

  US20030212100A1

文献信息

• Photoredox-Catalyzed Hydroxymethylation of Heteroaromatic Bases
  作者：Chelsea A. Huff、Ryan D. Cohen、Kevin D. Dykstra、Eric Streckfuss、Daniel A. DiRocco、Shane W. Krska

  DOI：10.1021/acs.joc.6b00811

  日期：2016.8.19

  We report the development of a method for room-temperature C–H hydroxymethylation of heteroarenes. A key enabling advance in this work was achieved by implementing visible light photoredox catalysis that proved to be applicable to many classes of heteroarenes and tolerant of diverse functional groups found in druglike molecules.

  我们报告了杂芳烃室温C–H羟甲基化方法的发展。这项工作取得了关键的进展，这是通过实施可见光光氧化还原催化来实现的，该催化被证明适用于多种类别的杂芳烃，并能耐受类药物分子中发现的各种官能团。
• QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF
  申请人：Mitsui Chemicals, Inc.

  公开号：EP1266888A1

  公开（公告）日：2002-12-18

  A quinoline derivative represented by the following formula (1): allows PPARα or γ which is an intranuclear transcription factor, to function strongly and is low in toxicity. By using this compound as an active ingredient, there can be provided a preventive or therapeutic agent for various diseases related to PPARα or γ.

  由下式（1）代表的喹啉衍生物： 可使作为核内转录因子的 PPARα 或 γ 发挥强大的功能，且毒性低。使用这种化合物作为活性成分，可以提供一种预防或治疗与 PPARα 或 γ 有关的各种疾病的药物。
• Quinoline derivatives and medicinal use thereof
  申请人：——

  公开号：US20030212100A1

  公开（公告）日：2003-11-13

  A quinoline derivative represented by the following formula (1): 1 allows PPAR&agr; or &ggr; which is an intranuclear transcription factor, to function strongly and is low in toxicity. By using this compound as an active ingredient, there can be provided a preventive or therapeutic agent for various diseases related to PPAR&agr; or &ggr;.

  由以下式（1）表示的喹啉衍生物，可以使作为细胞核转录因子的PPAR&agr;或&ggr;功能强大且毒性低。通过使用这种化合物作为活性成分，可以提供与PPAR&agr;或&ggr;相关的各种疾病的预防或治疗剂。
• A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist
  作者：Brian H Heasley、Renata Jarosz、Karen M Carter、S Jenny Van、Kevin R Lynch、Timothy L Macdonald

  DOI：10.1016/j.bmcl.2004.05.023

  日期：2004.8

  A recently reported dual LPA(1)/LPA(3) receptor antagonist (1) has been modified so as to modulate the basicity, sterics, and dipole moment of the 2-pyridyl moiety. Additionally, the implications of installing nonhydrolyzable phosphate head group isosteres with regard to antagonist potency and selectivity at LPA receptors is described. This study has resulted in the development of the first nonhydrolyzable and presumably phosphatase-resistant LPA(3)-selective antagonist reported to date. (C) 2004 Elsevier Ltd. All rights reserved.